Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,214
  • Shares Outstanding, K 71,075
  • Annual Sales, $ 570 K
  • Annual Income, $ -26,430 K
  • EBIT $ -62 M
  • EBITDA $ -61 M
  • 60-Month Beta 0.29
  • Price/Sales 54.07
  • Price/Cash Flow N/A
  • Price/Book 0.45
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.38
  • Most Recent Earnings $-0.13 on 03/11/25
  • Next Earnings Date 05/13/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 541.07% ( -95.81%)
  • Historical Volatility 84.05%
  • IV Percentile 83%
  • IV Rank 54.39%
  • IV High 930.51% on 02/28/25
  • IV Low 76.69% on 03/26/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 917
  • Open Int (30-Day) 994

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 4
  • High Estimate -0.13
  • Low Estimate -0.16
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4228 +4.12%
on 03/21/25
0.6156 -28.49%
on 02/25/25
-0.1302 (-22.83%)
since 02/24/25
3-Month
0.4228 +4.12%
on 03/21/25
1.0400 -57.67%
on 12/27/24
-0.5261 (-54.44%)
since 12/24/24
52-Week
0.4228 +4.12%
on 03/21/25
3.4500 -87.24%
on 04/30/24
-2.7598 (-86.24%)
since 03/22/24

Most Recent Stories

More News
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

OVID : 0.4402 (+3.55%)
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

OVID : 0.4402 (+3.55%)
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

OVID : 0.4402 (+3.55%)
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

OVID : 0.4402 (+3.55%)
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

OVID : 0.4402 (+3.55%)
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

OVID : 0.4402 (+3.55%)
Ovid Therapeutics to Host Investor Event

OVID : 0.4402 (+3.55%)
3 'Strong Buy'-Rated Stocks to Buy Now on the Dip

These outstanding growth stocks are worth buying on the dip.

AMZN : 203.07 (+3.50%)
$SPX : 5,762.88 (+1.68%)
GEHC : 81.69 (+0.25%)
GD : 265.74 (+0.88%)
OVID : 0.4402 (+3.55%)
TAK : 15.01 (-1.18%)
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the...

OVID : 0.4402 (+3.55%)
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate...

OVID : 0.4402 (+3.55%)

Business Summary

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved...

See More

Key Turning Points

3rd Resistance Point 0.4883
2nd Resistance Point 0.4748
1st Resistance Point 0.4499
Last Price 0.4402
1st Support Level 0.4115
2nd Support Level 0.3980
3rd Support Level 0.3731

See More

52-Week High 3.4500
Fibonacci 61.8% 2.2936
Fibonacci 50% 1.9364
Fibonacci 38.2% 1.5792
Last Price 0.4402
52-Week Low 0.4228

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar